Previous 10 | Next 10 |
Cortexyme, Inc. (CRTX) is down -19.4% as Citi initiated coverage on the stock with a ‘Sell’ rating. Noting that risks from ‘company’s “unique” Alzheimer’s disease approach are still not reflected in the stock even after the recen...
Gainers: China HGS Real Estate (HGSH) +136%.Pioneer Power Solutions (PPSI) +54%.Star Peak Energy Transition (STPK) +45%.Fangdd Network Group (DUO) +41%.Sutro Biopharma (STRO) +35%.Collective Growth (CGROU) +34%.CIIG Merger (CIIC) +31%.Collective Growth (CGRO) +27%.AquaBounty Technologies...
China HGS Real Estate (HGSH) +164%.Hexindai (HX) +32%.Sutro Biopharma (STRO) +25% as ovarian cancer drug study offers encouraging interim data.Domo (DOMO) +23% on Q3 results.CIIG Merger (CIIC) +22%.Sigma Labs (SGLB) +20%.Collective Growth Corporation (CGRO) +18%.Foresight Autonomous...
Cortexyme (CRTX) announces that, following an interim analysis by the independent Data Monitoring Committee ((DMC)) at the year 1 time point, the Phase 2/3 clinical trial, GAIN, evaluating lead candidate atuzaginstat (COR388) in patients with mild-to-moderate Alzheimer's disease ((AD)) w...
-- GAIN Trial passes futility analysis and will continue to 1-year endpoint following the independent Data Monitoring Committee recommendation; topline results expected on time in December 2021 -- -- Final study enrollment remains at 643; no sample size adjustment -- -...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. A ho...
Cortexyme (CRTX): Q3 GAAP EPS of -$0.73.Cash, cash equivalents and short term investments of $137.8MPress Release For further details see: Cortexyme reports Q3 results
— GAIN Trial enrollment complete with 643 participants — GAIN Trial interim analysis on schedule to complete in December 2020 Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering potential therapeutics for Alzheimer ...
-- Data demonstrate that patients enrolled in the GAIN Trial have baseline biomarkers consistent with Alzheimer’s disease and potential responders to atuzaginstat -- -- Press release issued in advance of CTAD presentation as an SEC exemption to the embargo policy, grant...
-- Oral presentation at Clinical Trials on Alzheimer's Disease 2020 will include baseline characteristics of the Phase 2/3 GAIN Trial ahead of planned interim analysis expected to occur before year-end 2020 -- -- Poster at Society for Immunotherapy of Cancer Annual Meeting eva...
News, Short Squeeze, Breakout and More Instantly...
New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the cor...
Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful ...
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus...